Fujifilm Biotechnologies, a contract development and manufacturing organization (CDMO), has appointed Christiane Bardroff as Chief Business Officer (CBO), effective June 1, 2026. Bardroff will lead commercial and sales, business insights and intelligence, strategic partnerships, and global marketing, reporting directly to President and CEO Lars Petersen.

“Christiane brings deep operational experience, strong customer understanding, and a proven ability to scale complex biologics organizations. She has delivered reliable results in highly regulated environments while building strong customer partnerships,” said Petersen. “Her leadership will strengthen how we integrate commercial, technical, and partnership capabilities, which is critical as our organization enters this next strategic growth phase.”

Henrik Ernlund, currently serving as interim Chief Commercial Officer, will continue as Head of Global Sales, effective June 1 to ensure continuity for customers and partners.

About Christiane Bardroff

Bardroff brings more than 18 years of experience and leadership across customer stewardship and biopharmaceutical operations, including process development and small-, mid-, and large-scale manufacturing, quality control, and quality assurance, as well as procurement, automation, and digitalization.

Most recently, Bardroff was Chief Operating Officer at Rentschler Biopharma SE. Previously, she advanced through roles of increasing responsibility at Teva Biotech and Roche.

Bardroff studied biotechnology and chemical engineering at Emden University of Applied Sciences in Germany and Zhejiang University of Science and Technology in Hangzhou, China.

“I am excited to join Fujifilm Biotechnologies at this important stage in its growth journey,” said Bardroff. “The company combines strong technical capabilities with a people-focused culture and a clear ambition to be a long-term partner across the biopharma landscape. I look forward to working with colleagues and customers across the globe to strengthen partnerships and support delivery of therapies to patients worldwide.”